标题
Beyond BRAF: where next for melanoma therapy?
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 112, Issue 2, Pages 217-226
出版商
Springer Nature
发表日期
2014-09-03
DOI
10.1038/bjc.2014.476
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
- (2014) Moriah H. Nissan et al. CANCER RESEARCH
- Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
- (2014) M. A. Wilson et al. CLINICAL CANCER RESEARCH
- Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
- (2014) Antoni Ribas et al. LANCET ONCOLOGY
- Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics
- (2014) Vito W. Rebecca et al. MOLECULAR & CELLULAR PROTEOMICS
- Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma
- (2014) Edward J. Hartsough et al. MOLECULAR CANCER RESEARCH
- Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
- (2014) J. Acquaviva et al. MOLECULAR CANCER THERAPEUTICS
- MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
- (2014) J. Asundi et al. MOLECULAR CANCER THERAPEUTICS
- A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance
- (2014) J. Xia et al. MOLECULAR CANCER THERAPEUTICS
- Copper is required for oncogenic BRAF signalling and tumorigenesis
- (2014) Donita C. Brady et al. NATURE
- Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin inBRAFwild-type melanoma
- (2014) Vito W. Rebecca et al. Pigment Cell & Melanoma Research
- Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
- (2014) Alexander M. Menzies et al. PLoS One
- Patterns of response and progression in patients withBRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib
- (2013) Mary W. F . Azer et al. CANCER
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
- (2013) K. L. Nathanson et al. CLINICAL CANCER RESEARCH
- BRAF in Melanoma: Current Strategies and Future Directions
- (2013) A. K. S. Salama et al. CLINICAL CANCER RESEARCH
- Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
- (2013) F. Catalanotti et al. CLINICAL CANCER RESEARCH
- BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition
- (2013) K. E. Hutchinson et al. CLINICAL CANCER RESEARCH
- Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
- (2013) Victoria Marsh Durban et al. JOURNAL OF CLINICAL INVESTIGATION
- P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma
- (2013) Christy C. Ong et al. JNCI-Journal of the National Cancer Institute
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
- (2013) Caroline Robert et al. LANCET ONCOLOGY
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
- (2013) H. E. Haarberg et al. MOLECULAR CANCER THERAPEUTICS
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
- (2013) Gunther Zimmermann et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
- (2013) Thomas Botton et al. Pigment Cell & Melanoma Research
- Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
- (2013) Xinqi Wu et al. PLoS One
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
- (2013) C. Posch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- (2013) Jessie Villanueva et al. Cell Reports
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- (2012) Piro Lito et al. CANCER CELL
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
- (2012) K. H. T. Paraiso et al. CLINICAL CANCER RESEARCH
- RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
- (2012) Y. Su et al. CLINICAL CANCER RESEARCH
- Sunitinib Therapy for Melanoma Patients withKITMutations
- (2012) David R. Minor et al. CLINICAL CANCER RESEARCH
- BRAF inhibitor activity in V600R metastatic melanoma
- (2012) Oliver Klein et al. EUROPEAN JOURNAL OF CANCER
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
- (2012) Michael Krauthammer et al. NATURE GENETICS
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
- (2012) Christine M. Lovly et al. PLoS One
- Elucidating Distinct Roles for NF1 in Melanomagenesis
- (2012) Ophélia Maertens et al. Cancer Discovery
- BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
- (2012) Kimberly Brown Dahlman et al. Cancer Discovery
- Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
- (2011) K. Tworkoski et al. MOLECULAR CANCER RESEARCH
- ERK and PDE4 cooperate to induce RAF isoform switching in melanoma
- (2011) Amélie Marquette et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Resistance to BRAF Inhibition in Melanomas
- (2011) David B. Solit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
- (2011) Bianca Devitt et al. Pigment Cell & Melanoma Research
- BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
- (2011) Hazem El-Osta et al. PLoS One
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- (2010) K H T Paraiso et al. BRITISH JOURNAL OF CANCER
- Bevacizumab and everolimus in the treatment of patients with metastatic melanoma
- (2010) John D. Hainsworth et al. CANCER
- A Mouse Model of Melanoma Driven by Oncogenic KRAS
- (2010) C. Milagre et al. CANCER RESEARCH
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
- (2010) J. A. Ellerhorst et al. CLINICAL CANCER RESEARCH
- Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
- (2010) P J Mishra et al. ONCOGENE
- BRAF Signaling and Targeted Therapies in Melanoma
- (2009) Nathalie Dhomen et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
- (2009) Bijay S. Jaiswal et al. PLoS One
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SnapShot: Ras Signaling
- (2008) Megan Cully et al. CELL
- Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement
- (2008) Victoria Sanz-Moreno et al. CELL
- OncogenicNRAShas multiple effects on the malignant phenotype of human melanoma cells culturedin vitro
- (2008) Malihe Eskandarpour et al. INTERNATIONAL JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started